Modification of dendritic cells with interferon‐γ‐inducible protein‐10 gene to enhance vaccine potency
- 20 July 2009
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 11 (10), 889-898
- https://doi.org/10.1002/jgm.1371
Abstract
Background Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8+ T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs. Methods We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined. Results The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8+ T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10. Conclusions The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA VaccinationCancer Research, 2007
- TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferationBlood, 2006
- CD8+ T‐cell memory in tumor immunology and immunotherapyImmunological Reviews, 2006
- Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartmentsImmunology Letters, 2006
- Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse modelVaccine, 2006
- Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulinVaccine, 2004
- The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycanMolecular Therapy, 2004
- Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell deathGene Therapy, 2004
- Sphingosine 1‐phosphate induces Chemotaxis of immature dendritic cells and modulates cytokine‐release in mature human dendritic cells for emergence of Th2 immune responsesThe FASEB Journal, 2002
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991